Patients undergoing primary total hip replacement were included in this randomized controlled trial to evaluate the comparative efficacy of oral and intravenous tranexamic acid (TXA) in reducing blood loss and limiting the need for blood transfusions. The number of patients included in this trial was not clearly reported in the conference abstract, but a power calculation was conducted that indicated a need for 50 patients in each group. The results of this trial indicate that there were no significant differences in postoperative hemoglobin drop, transfusion rate, or complication rate observed between groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
